LQDA Key Statistics, Chart & Performance
The current stock price of LQDA is 32.59 USD. In the past month the price increased by 15.12%. In the past year, price increased by 198.44%.
LQDA Latest News, Press Relases and Analysis
LQDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.9 | 954.25B | ||
| JNJ | JOHNSON & JOHNSON | 20.23 | 505.98B | ||
| MRK | MERCK & CO. INC. | 11.24 | 245.74B | ||
| PFE | PFIZER INC | 8.06 | 146.69B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.8 | 104.23B | ||
| ZTS | ZOETIS INC | 18.56 | 51.85B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.44 | 22.40B | ||
| VTRS | VIATRIS INC | 4.97 | 13.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.16 | 10.57B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.01 | 9.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.24B |
Related stock screener links
About LQDA
Company Profile
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Company Info
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560 US
CEO: Neal Fowler
Employees: 157
Phone: 19193284400
LIQUIDIA CORP / LQDA FAQ
What does LIQUIDIA CORP do?
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
What is the current price of LQDA stock?
The current stock price of LQDA is 32.59 USD. The price decreased by -0.28% in the last trading session.
Does LIQUIDIA CORP pay dividends?
LQDA does not pay a dividend.
How is the ChartMill rating for LIQUIDIA CORP?
LQDA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of LIQUIDIA CORP (LQDA)?
LIQUIDIA CORP (LQDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).
How many employees does LIQUIDIA CORP have?
LIQUIDIA CORP (LQDA) currently has 157 employees.
Can you provide the short interest for LQDA stock?
The outstanding short interest for LIQUIDIA CORP (LQDA) is 21.68% of its float.
LQDA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 97.36% of all stocks.
LQDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LQDA. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative.
LQDA Financial Highlights
Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 11.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.15% | ||
| ROE | -552.55% | ||
| Debt/Equity | 6.19 |
LQDA Forecast & Estimates
15 analysts have analysed LQDA and the average price target is 44.88 USD. This implies a price increase of 37.71% is expected in the next year compared to the current price of 32.59.
For the next year, analysts expect an EPS growth of 47.3% and a revenue growth 767.98% for LQDA